Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cell transplant Patients' vaccine response under the microscope

NCT ID NCT03659773

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at how well recommended vaccines protect adults who have had a stem cell transplant. Researchers took blood samples from 152 transplant recipients before and after vaccination to measure antibody levels against diseases like tetanus, diphtheria, and hepatitis B. The goal was to understand if the vaccines trigger a strong immune response in these patients, who are at high risk for infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors improve vaccination schedules for stem cell transplant recipients, reducing their risk of serious infections.
What could go wrong
This is an observational study, not a treatment trial. It only measures immune responses and does not test a new vaccine or therapy, so direct patient benefits are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

152 people

The number who actually took part.

Started

Apr 2018

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * allogeneic and autologous HSCT recipients * ≥ 18 year-old * patients having been informed of the conditions of the study (24-month follow-up) and having signed the informed consent form * Person with social security insurance • Additional inclusion criteria for healthy volunteers enrolled (10 volunteers)in the ancillary study of influenza vaccine response: * health-care workers recruited from the hospital staff Exclusion Criteria: * Patient with innate or acquired immune deficiency (severe combined immunodeficiency, Hepatitis C virus (HCV), HBV, HIV infections at any stage) * Pregnant or breastfeeding women * History of previous severe allergic reaction to vaccine components * Patient with no social security coverage, with restricted liberty or under legal protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic stem cells are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic stem cells Vaccination

Contacts and locations

Locations

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Hôpital de la Croix Rousse

    Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.